Press Releases

 
Press Releases
  Date Title and Summary View
Jan 19, 2017
SAN DIEGO, Jan. 19, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests to improve the management of cancer patients, announces that it has been awarded Australian Patent No. 2010229924 entitled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The issued patent covers the u...
Dec 27, 2016
SAN DIEGO, Dec. 27, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announces that Columbia University Medical Center will conduct a study to evaluate the clinical utility of the Company's Target Selector™ platfor...
Dec 8, 2016
SAN DIEGO, Dec. 8, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests to improve the management of cancer patients, announces that clinical data featuring its Target Selector™ Circulating Tumor Cell platform demonstrated high concordance to tissue biopsy for the detect...
Dec 7, 2016
SAN DIEGO, Dec. 7, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests to improve the management of cancer patients, announces the analytical validation study results for its blood-based PD-L1 assay, which demonstrate the highly sensitive, specific, and reproducible performan...
Nov 21, 2016
SAN DIEGO, Nov. 21, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview ...
Nov 9, 2016
SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, reports financial results for the three and nine months ended September 30, 2016, and provides ...
Oct 31, 2016
SAN DIEGO, Oct. 31, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable  information to physicians to improve cancer treatment, announces that it will release financial results for the three and nine months ended Septembe...
Oct 27, 2016
SAN DIEGO, Oct. 27, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces the appointment of David Moskowitz to the newly created position of Vice President, ...
Oct 20, 2016
SAN DIEGO, Oct. 20, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide information to physicians to improve cancer treatment, announces that clinical results from a study evaluating 40 patients with advanced non-small cell lung cancer (NSCLC)...
Oct 19, 2016
SAN DIEGO, Oct. 19, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces the closing of its previously announced underwritten public offering of 9,100,000 shares of...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase